NeOnc CEO Buys More Shares Below $5 as NTHI Secures FDA Meeting to Discuss Phase 3 Trial

Recent purchases total 150,000 shares as NeOnc prepares to discuss potential accelerated approval and a Phase 3 confirmatory trial for NEO100

DALLAS, Nov. 12, 2026 (GLOBE NEWSWIRE) -- (www.InvestorsTape.com)— NeOnc Technologies Holdings (NASDAQ: NTHI) CEO Amir Heshmatpour has purchased another 70,000 shares in the open market, bringing his recent purchases to 150,000 shares as the company approaches important clinical and regulatory milestones.

The latest transactions represent approximately $294,500, with purchases reaching $4.49 per share. Combined with the preceding 80,000-share purchases announced by NeOnc, Heshmatpour committed approximately $563,582 across November 5–11.

Our bullish interpretation: the CEO continues putting personal capital behind his conviction as NeOnc’s development story advances.

The CEO Keeps Buying Higher

The latest filing summary details three purchases:

Transaction date	Shares purchased	Reported price
November 10	50,000	$4.192 weighted average
November 11	10,000	$4.49
November 11	10,000	$4.00
Total	70,000	Approximately $4.207 average

The transactions increased Heshmatpour’s reported direct holdings to 3,333,000 shares, separate from his indirectly held positions.

NeOnc previously announced purchases of 80,000 shares across November 5, 6 and 9, totaling approximately $269,082 using personal funds.

The progression stands out. Earlier purchases came in the low-to-mid $3 range. The CEO continued adding above $4, including a transaction at $4.49.

These open-market purchases increase his ownership as investors evaluate the company’s next milestones. Roth MKM also recently reaffirmed its Buy rating and $20 price target, maintaining its bullish valuation.

FDA Meeting Puts Phase 3 and Accelerated Approval on the Agenda

On November 11, NeOnc announced that the FDA granted a Type B End-of-Phase meeting scheduled for early January 2027 to discuss a potential accelerated approval pathway for intranasal NEO100.

NeOnc intends to seek feedback on whether its clinical and nonclinical evidence could support an accelerated approval application for recurrent or progressive IDH-mutant grade 4 astrocytoma.

The company will also seek agreement on NEO100-012, a proposed randomized Phase 3 trial comparing NEO100 with investigator-selected standard-of-care chemotherapy. Overall survival would be the primary endpoint, with the study intended to provide registrational and confirmatory evidence.

NeOnc now has an FDA discussion scheduled around a potential approval pathway and the design of a Phase 3 trial. Positive Phase 2a findings provide the foundation for that discussion and give investors a defined next step to follow.

Two Programs. Several Dates to Watch.

The January meeting adds to an already active calendar:

• November 13: Updated NEO100 Phase 1/2a results and NEO212 Phase 1 data are scheduled for presentation at the Society for Neuro-Oncology Annual Meeting.
• November 17: NeOnc’s FDA End-of-Phase 1 meeting for NEO212 is scheduled to address proposed Phase 2 development and next steps.
• Early January 2027: The newly announced NEO100 meeting will address its potential accelerated approval pathway and proposed Phase 3 trial.

Two investigational drugs, upcoming scientific presentations, separate FDA discussions and continued CEO buying give investors several developments to watch.

A Larger Short Position Adds Potential Fuel

The latest short-interest update puts NTHI at approximately 921,000 shares short as of October 30, compared with 876,682 on October 15.

That represents an increase of roughly 44,000 shares before the stock’s recent advance through $4.

Updated NEO100 data and NEO212 Phase 1 findings are scheduled for presentation at this week’s Society for Neuro-Oncology annual meeting.

About InvestorsTape.com

At InvestorsTape.com, our mission is simple: deliver financial news that cuts through the noise and shines a spotlight on the companies, innovations, and market forces shaping the next decade of growth. In a landscape dominated by high-frequency headlines and fleeting narratives, we bring clarity, depth, and balance to the stories that matter, helping investors discover high-potential companies and evaluate emerging opportunities with confidence.

Contact
benh@investorstape.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements that may regard NeOnc Technologies Holdings’ future revenue, growth trajectory, profitability outlook, expansion plans, strategic partnerships, potential regulatory approvals, and other projections, plans, and objectives. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including market conditions, timing of venue openings, execution risks, operational performance, competition, regulatory matters, and general economic conditions. Readers should not place undue reliance on these statements, which speak only as of the date made.

General Disclaimer:
InvestorsTape.com has been compensated for press and editorial coverage of NeOnc Technologies Holdings and further disclosure information is available here. This communication is provided for informational and journalistic purposes only and reflects the independent editorial views of InvestorsTape.com.

This editorial discusses investigational therapy and clinical-trial results and is not medical advice or a recommendation to buy or sell securities. This publication is protected speech under the First Amendment of the United States Constitution. Nothing herein constitutes an offer, solicitation, or recommendation to buy or sell any security, nor should it be construed as investment advice. Investing in securities involves risk, including the possible loss of principal. Readers are encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decision.